• Profile
Close

Stopping a tiny—and deadly—fly in its tracks

Brigham Young University Health News Jul 07, 2018

Sixty million people in sub-Saharan Africa live at risk of African sleeping sickness, a disease caused by parasites transmitted through the tsetse fly. In the late stage of the disease, when the parasite crosses the blood-brain barrier, the results are oftentimes fatal.

BYU chemistry professor Ken Christensen, students, and collaborators at Clemson University have developed an innovative technique using biosensors to monitor the glucose level of Trypanasoma brucei parasites, which could in turn help develop treatments for the sleeping sickness.

“The unique thing about the T. brucei parasite is that it relies on host glucose for survival,” said Christensen, whose study was recently published in PLOS Neglected Tropical Diseases. “We know that if you could deprive the parasites in the bloodstream of glucose, the parasite will die.”

For the study, Christensen tested glucose levels to monitor the metabolism of the parasites using a genetically encoded glucose biosensor. The biosensor combines three proteins: a cyan florescent protein, a glucose-binding protein, and a yellow florescent protein.

When the glucose-binding protein interacts with glucose in the parasite, the two fluorescent proteins move closer together. Christensen then uses the spectroscopic changes to monitor the fluorescence-intensity ratio between the yellow and cyan proteins. When the proteins are far apart, the blue light from the cyan fluorescent protein remains. But as the proteins move closer together, the blue light goes down and the yellow light from the yellow fluorescent protein increases.

This ratio is proportional to the glucose level in the parasite.

The results obtained from the biosensor provide new insights into the process through which parasites acquire and transport glucose for survival and provide a means to identify molecules that disrupt glucose levels in the parasite.

“In the long run, we hope that some of the glucose-disrupting molecules we are now identifying can be developed into therapeutics to treat African sleeping sickness,” Christensen said.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay